MassMutual Private Wealth & Trust FSB Raises Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• MassMutual Private Wealth & Trust FSB has increased its stake in Vertex Pharmaceuticals by 57.4%, now owning 26,791 shares valued at approximately $11.9 million.
• Vertex Pharmaceuticals has received a mix of ratings from analysts, with a consensus target price of $496.05 and 14 analysts rating it as a Buy.
• In recent insider activity, Director Bruce I. Sachs purchased 5,000 shares of Vertex stock for around $1.95 million, increasing his total shares to 45,000.

MassMutual Private Wealth & Trust FSB increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 57.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,791 shares of the pharmaceutical company's stock after buying an additional 9,775 shares during the period. MassMutual Private Wealth & Trust FSB's holdings in Vertex Pharmaceuticals were worth $11,927,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of VRTX. Activest Wealth Management bought a new position in Vertex Pharmaceuticals in the first quarter worth approximately $25,000. Clal Insurance Enterprises Holdings Ltd raised its stake in Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 45 shares in the last quarter. Mascagni Wealth Management Inc. bought a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $31,000. Flaharty Asset Management LLC bought a new position in Vertex Pharmaceuticals in the first quarter worth approximately $32,000. Finally, Mpwm Advisory Solutions LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $40,000. Institutional investors own 90.96% of the company's stock.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of recent research reports. Morgan Stanley set a $439.00 price objective on shares of Vertex Pharmaceuticals and gave the stock an "equal weight" rating in a research note on Tuesday, August 5th. HC Wainwright reduced their price target on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating on the stock in a research report on Tuesday, August 5th. BMO Capital Markets set a $530.00 price target on Vertex Pharmaceuticals and gave the stock an "outperform" rating in a research report on Tuesday, August 5th. Scotiabank reduced their price target on Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating on the stock in a research report on Tuesday, August 5th. Finally, Raymond James Financial assumed coverage on Vertex Pharmaceuticals in a research report on Tuesday, September 2nd. They set a "market perform" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and thirteen have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $496.05.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs acquired 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director owned 45,000 shares of the company's stock, valued at approximately $17,535,600. This represents a 12.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Trading Down 0.3%

NASDAQ:VRTX opened at $393.21 on Tuesday. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The firm has a fifty day simple moving average of $421.34 and a 200-day simple moving average of $452.63. The company has a market capitalization of $100.82 billion, a P/E ratio of 28.11 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same period in the previous year, the firm posted ($12.83) earnings per share. The business's revenue for the quarter was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.